Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (18 ops.)
Latest filing published 14 Sept 2026 for Amylyx Pharmaceuticals, Inc., €816k. Read the official filing
Filing timeline
BuySaleJoshua B. Cohen
Insider track record
Disclosed buys
0
Disclosed sells
18
Signal history
Joshua B. Cohen: trading record in brief
Joshua B. Cohen (chief executive) discloses dealings in Amylyx Pharmaceuticals, Inc. to SEC (Form 4). Between 6 January 2022 and 10 September 2026, the trades on record add up to 30 filings.
No open-market purchase appears, only 18 sales worth €6.9M. Outside the open market, there are 5 share grants and 6 option exercises. Since January 2026: no purchases and 7 sales on the market.
Most recently, on 14 September 2026, the filings show an open-market sale worth €816k in Amylyx Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Joshua B. Cohen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations30 total
29,545 shares@ US$32.15570.024% mcap8.8% of flowCommon StockSEC:0001193125-26-390507:0
919 shares@ US$33.14880.0008% mcap0.3% of flowCommon StockSEC:0001193125-26-390507:1
60,039 shares0Common StockSEC:0001193125-26-359675:0
248,865 shares0Common StockSEC:0001193125-26-098440:0
29,282 shares@ US$14.4843.9% of flowCommon StockSEC:0001193125-26-091442:0
15,500 shares@ US$14.68342.1% of flowCommon StockSEC:0001193125-26-037552:0
197,182 shares@ US$7.5713.8% of flowCommon StockSEC:0001193125-26-017057:0
136,193 shares@ US$13.589517.1% of flowCommon StockSEC:0001193125-26-017057:1
2,818 shares@ US$7.570.2% of flowCommon StockSEC:0001193125-26-017057:2
1,974 shares@ US$13.82930.3% of flowCommon StockSEC:0001193125-26-017057:3
7,715 shares@ US$11.09480.8% of flowCommon StockSEC:0001193125-26-007666:0
29,733 shares@ US$14.34333.9% of flowCommon StockSEC:0001193125-25-228340:0
21,490 shares@ US$3.46590.7% of flowCommon StockSEC:0000950170-25-049513:0
180,118 shares0Common StockSEC:0000950170-25-036708:0
4,595 shares@ US$3.16630.2% of flowCommon StockSEC:0000950170-25-033719:0
11,851 shares@ US$3.46870.4% of flowCommon StockSEC:0000950170-25-014610:0
7,471 shares@ US$4.04660.3% of flowCommon StockSEC:0000950170-25-003531:0
18,589 shares@ US$3.19620.6% of flowCommon StockSEC:0000950170-24-111811:0
1,857 shares@ US$1.570.0% of flowCommon StockSEC:0000950170-24-109397:0
34,449 shares@ US$1.570.5% of flowCommon StockSEC:0000950170-24-106915:0
179,850 shares0Common StockSEC:0000950170-24-045696:0
4,135 shares@ US$18.72790.8% of flowCommon StockSEC:0000950170-24-027923:0
126,667 shares0Common StockSEC:0000950170-24-022413:0
5,841 shares@ US$16.32810.9% of flowCommon StockSEC:0000950170-24-003981:0
63,694 shares@ US$1.571.0% of flowCommon StockSEC:0000950170-23-065259:0
25 of 30 declarations
